Skip to main content
New Startings
Telehealth

GLP-1s and Telehealth: A Complete Guide

Charles Yang
A laptop set up for a virtual appointment beside a glass of water and a small plant

GLP-1 medications are now the most talked-about weight-loss treatment in the US, and telehealth companies are one of the main ways people get them. A short online visit, a prescription, and a box shipped to your door has replaced weeks of waiting for an in-person appointment.

That convenience came with confusion. Patients see brand names like Wegovy and Zepbound next to cheaper “compounded semaglutide” offers, and prices that range from under $150 to over $1,300 a month. The rules on compounded versions have also changed sharply since 2025.

This guide explains what GLP-1s are, how branded and compounded versions differ, why compounded drugs cost less, how telehealth programs work, and how to choose one safely. Prices and regulations change often, so treat the figures below as a snapshot and confirm current details before you buy.

What GLP-1s are and how they work

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. GLP-1 receptor agonists are drugs that mimic this hormone, but they last far longer in the body than the natural version.

They work in several ways at once:

  • Appetite and fullness. They act on brain areas that control hunger, so people feel full sooner and think about food less.
  • Slower digestion. They slow how quickly the stomach empties, which stretches out that feeling of fullness.
  • Blood sugar control. They help the pancreas release insulin when blood sugar rises and reduce glucagon, a hormone that raises blood sugar.

These drugs were first developed for type 2 diabetes. Researchers then saw consistent weight loss and ran dedicated obesity trials. In the major trials, semaglutide 2.4 mg produced average weight loss of roughly 15% over about 68 weeks, and tirzepatide at its highest dose produced roughly 20% over about 72 weeks, alongside diet and exercise.

Tirzepatide is technically a dual agonist. It activates both GLP-1 and GIP receptors, which is one reason it tends to produce more weight loss. It is usually grouped with GLP-1s in everyday conversation.

One point matters for anyone considering treatment: these are long-term medications. Studies show that most people regain a large share of the weight after stopping, so the cost question is really a monthly cost for as long as you stay on it.

Branded GLP-1 drugs and what they cost

Two companies make nearly all FDA-approved GLP-1 weight-loss drugs in the US. Novo Nordisk is the only maker of approved semaglutide (Wegovy, plus Ozempic for diabetes). Eli Lilly is the only maker of approved tirzepatide (Zepbound, plus Mounjaro for diabetes).

The market moved quickly in 2026. Novo launched the Wegovy pill, a daily oral semaglutide, in January after its December 2025 approval. Lilly’s daily pill Foundayo (orforglipron) was approved and became available in April 2026.

List prices still top $1,000 a month, but few people pay them. Both companies now sell directly to cash-paying patients at much lower prices:

Branded GLP-1 prices reported in the October 6, 2026 guide. Confirm current pricing and eligibility.
DrugFormList priceManufacturer self-pay price
WegovyWeekly injection$1,349/month$349/month (0.25–2.4 mg)
Wegovy pillDaily tabletabout $1,350/month$149–$299/month by dose
ZepboundWeekly injectionup to $1,086/month$299 (2.5 mg), $399 (5 mg), $449 (7.5 mg+)
FoundayoDaily tabletnot listed herefrom $149/month; most around $349

With commercial insurance that covers the drug, manufacturer savings cards can bring costs down to as little as $25 a month. Many employer plans still exclude weight-loss drugs, though.

Medicare has a new option. A temporary CMS program called the Medicare GLP-1 Bridge started July 1, 2026 and runs through December 31, 2027. It offers Wegovy, Foundayo and the Zepbound KwikPen for $50 a month to people who meet specific weight and health criteria (details).

How telehealth GLP-1 companies work

Most telehealth weight-loss programs follow the same basic path:

  1. Online intake. You fill out a health questionnaire covering weight, height, medical history and current medications. Some programs ask for lab work or a photo ID.
  2. Clinician review. A licensed doctor, nurse practitioner or physician assistant reviews your answers, sometimes by video and sometimes asynchronously by message.
  3. Prescription. If you qualify, the clinician prescribes a branded or compounded GLP-1. FDA labels generally cover adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
  4. Delivery. A partner pharmacy ships the medication, often in a cold pack, along with needles or syringes if needed.
  5. Follow-up. Most programs check in monthly to adjust the dose and track side effects, usually through an app or messaging.

An important detail is that many telehealth brands are not themselves medical practices or pharmacies. They are platforms that connect you to an affiliated clinician network and to one or more outside pharmacies. That is why it matters who actually prescribes and who actually fills your medication.

Pricing models vary. Some charge one bundled monthly fee that includes the visit, drug and shipping. Others charge a separate membership fee, and you buy the medication on top of it, sometimes through your insurance or a manufacturer program. A low advertised drug price can nearly double once required fees are added, so compare the total monthly cost.

The line between branded and compounded programs has also blurred. In March 2026, Novo Nordisk and Hims & Hers reached a deal to offer FDA-approved Wegovy and Ozempic on that platform, and Novo dropped its patent lawsuit (source). Several large platforms now offer brand-name drugs at or near manufacturer cash prices.

Compounded GLP-1s: why they’re cheaper and where they stand legally

Compounded drugs are custom-made by pharmacies rather than mass-produced by the original manufacturer. Compounded semaglutide and tirzepatide use the same active ingredient as the brands, but they are not FDA-approved and are not generics. The FDA does not review them for safety, effectiveness or quality before sale.

Why compounded versions cost less

Compounded GLP-1s have consistently been cheaper than branded drugs for several reasons:

  • No research costs to recover. Novo and Lilly spent billions on clinical trials. Compounders skip trials entirely.
  • Bulk active ingredient. Pharmacies buy raw drug substance and mix it themselves, rather than buying finished pens.
  • Simpler packaging. Compounded doses usually ship in multi-dose vials with syringes instead of engineered auto-injector pens.
  • No brand pricing power. Many pharmacies and platforms compete for the same customers, pushing prices down.

The gap is real but narrower than it was. Compounded semaglutide commonly sells for roughly $149 to $299 a month through telehealth, with tirzepatide somewhat higher (source). Brand-name cash prices of $149 to $449 now overlap that range, especially for oral Wegovy and starting doses of Zepbound.

The legal picture has changed

Compounding pharmacies were allowed to mass-produce copies only because the brands were in shortage. The FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025. The final wind-down deadlines ended on May 22, 2025 (source).

Since then, enforcement has tightened. The FDA sent warning letters to telehealth sellers in waves, including 30 companies in February 2026 and 25 more in June 2026, over claims like “same as Wegovy” or “from an FDA-approved pharmacy” (source). On May 1, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the list that lets large outsourcing facilities compound from bulk ingredients. As of this writing, a final decision had not been published.

Compounding is not completely banned. A state-licensed pharmacy can still make a version for an individual patient when a prescriber documents a meaningful clinical difference, such as an allergy to an ingredient in the brand. Large subscription businesses do not fit easily inside that exception.

Safety, side effects and risks

GLP-1s are generally well studied, but they are not risk-free. The most common side effects are digestive: nausea, vomiting, diarrhea, constipation and stomach pain. These are usually worst when starting or raising a dose, which is why doses are increased gradually over several months.

Less common but serious risks listed on the labels include pancreatitis, gallbladder problems such as gallstones, kidney problems from dehydration, and low blood sugar when combined with some diabetes drugs. The injectable brands carry a boxed warning about thyroid C-cell tumors seen in rodent studies. People with a personal or family history of medullary thyroid cancer or MEN 2 syndrome should not use them. GLP-1s are also not recommended during pregnancy.

Compounded versions add risks of their own:

  • Dosing errors. Pens meter each dose automatically, but vials require you to draw up the right amount. The FDA has documented patients taking 5 to 20 times their intended dose after mixing up milligrams, milliliters and units (source).
  • Ingredient quality. The FDA has warned about products made with salt forms such as semaglutide sodium, which are different from the approved active ingredient.
  • Adverse event reports. As of May 31, 2026, the FDA had received about 990 adverse event reports for compounded semaglutide and over 730 for compounded tirzepatide, a count it says is likely low.

Whichever version you use, never change your dose or stop abruptly without talking to your prescriber. Seek urgent care for severe, persistent stomach pain, signs of dehydration, or symptoms of an allergic reaction.

How to choose a telehealth GLP-1 provider

A good program looks a lot like good in-person care, delivered online. Use this checklist before you sign up:

  • Real medical screening. The intake should ask detailed health questions and screen out people who shouldn’t take GLP-1s. Instant approval with no questions is a red flag.
  • Licensed clinicians in your state. Confirm who prescribes and that they are licensed where you live.
  • A named, licensed pharmacy. Ask in writing which pharmacy fills your prescription, then check it against your state board of pharmacy database.
  • Honest marketing. Avoid any company claiming a compounded drug is “the same as,” “generic” or “FDA-approved.” The FDA has cited those exact claims as illegal.
  • Clear total pricing. Get the full monthly cost, including membership fees, dose increases and shipping. Watch for prices that jump as your dose goes up.
  • Ongoing follow-up. Look for regular check-ins, a way to reach a clinician about side effects, and help adjusting doses.
  • Brand-name options. Providers that offer both FDA-approved and compounded drugs let you compare costs honestly.
  • Easy cancellation. Avoid long prepaid contracts you can’t exit.

Before choosing compounded, price the branded options. Check whether your insurance covers a GLP-1, whether you qualify for the Medicare Bridge, and what LillyDirect or NovoCare charge for your dose. For many people in 2026, the brand-name drug now costs about the same or only slightly more.

The bottom line

GLP-1s are effective, long-term medications for weight management and type 2 diabetes, and telehealth has made them far easier to get. Compounded versions became popular because they cost less, thanks to skipped trials, bulk ingredients and simpler packaging.

That price advantage has shrunk as manufacturers cut cash prices to $149 to $449 a month, while the legal and safety questions around compounded drugs have grown. The smartest approach is to compare the total monthly cost of each option, verify who prescribes and who fills your medication, and make the decision with a licensed clinician.

This article is for general information and is not medical advice. Talk with a healthcare provider before starting, changing or stopping any medication.

Sources